Effect of nanoencapsulation using poly (lactide-co-glycolide) (PLGA) on anti-angiogenic activity of bevacizumab for ocular angiogenesis therapy

Zhang, Xiao-Pei; Sun, Jianguo; Yao, Jin; Shan, K. Y.; Liu, Bai-Hui; Yao, Mengfei; Ge, Huan; Jiang, Qin; Zhao, Chunxia; Yan, Biao

doi:10.1016/j.biopha.2018.08.092

Cited by 57 publications

(57 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was no evidence of ocular toxicity after the ocular administration of these nanoparticles, whereas the distribution in posterior segment tissues such as retina, choroid and sclera was observed, along with a concentration decrease 7–56 days after administration 113 . Similar results were observed with other nanoparticles in which the maximum concentration of bevacizumab in the vitreous body and aqueous humor was observed at about 6 days after bevacizumab‐loaded PLGA‐nanoparticles injection, which showed a significantly greater half‐life than the bevacizumab solution 109 . Comparable results were observed for bevacizumab‐loaded nanoparticles based on mesoporous silica, in which the maximum concentration of bevacizumab in the vitreous and aqueous humor was observed at about 7 days after the formulation injection 114 …”

Section: Nanoparticulate Systems For Bd Delivery Intended For Ocular supporting

confidence: 77%

“…An in vitro study showed a pH‐dependent bevacizumab release profile during 168 hours, 103 with a bevacizumab sustained release at around 14% in a buffer, pH = 7.4. Other study showed that bevacizumab experienced an initial burst release with more than 40% of bevacizumab released from bevacizumab‐encapsulated PLGA in the first 2 hours in phosphate‐buffered saline, another sustained release (40%) in the next 7 days, followed by a slow drug release for up to 21 days 109 . Also, a very slow and consistent drug release was obtained with chitosan‐coated PLGA nanoparticles of bevacizumab that did not achieve complete release until 72 hours (maximum 25%) 108 .…”

Section: Nanoparticulate Systems For Bd Delivery Intended For Ocular mentioning

confidence: 99%

“…PLGA is composed of lactic acid and glycolic acid, and it is widely used in drug delivery systems due to its biodegradability and biocompatibility. 105 Generally, bevacizumab-loaded PLGA nanoparticles have a size around 200-300 nm 103,[106][107][108] or even smaller 109 110 In other work, bevacizumab structure was studied after encapsulation in PLGA-nanoparticles and after release from PLGA-nanoparticles.…”

Section: Nanoparticles Based On Polymersmentioning

confidence: 99%

See 2 more Smart Citations

Biological drug therapy for ocular angiogenesis: Anti‐VEGF agents and novel strategies based on nanotechnology

Formica

Alfonso

Palma

2021

Pharmacology Res & Perspec

View full text Add to dashboard Cite

Currently, biological drug therapy for ocular angiogenesis treatment is based on the administration of anti‐VEGF agents via intravitreal route. The molecules approved with this purpose for ocular use include pegaptanib, ranibizumab, and aflibercept, whereas bevacizumab is commonly off‐label used in the clinical practice. The schedule dosage involves repeated intravitreal injections of anti‐VEGF agents to achieve and maintain effective concentrations in retina and choroids, which are administrated as solutions form. In this review article, we describe the features of different anti‐VEGF agents, major challenges for their ocular delivery and the nanoparticles in development as delivery system of them. In this way, several polymeric and lipid nanoparticles are explored to load anti‐VEGF agents with the aim of achieving sustained drug release and thus, minimize the number of intravitreal injections required. The main challenges were focused in the loading the molecules that maintain their bioactivity after their release from nanoparticulate system, followed the evaluation of them through studies of formulation stability, pharmacokinetic, and efficacy in in vitro and in vivo models. The analysis was based on the information published in peer‐reviewed published papers relevant to anti‐VEGF treatments and nanoparticles developed as ocular anti‐VEGF delivery system.

show abstract

Section: Nanoparticulate Systems For Bd Delivery Intended For Ocular supporting

confidence: 77%

Section: Nanoparticulate Systems For Bd Delivery Intended For Ocular mentioning

confidence: 99%

Section: Nanoparticles Based On Polymersmentioning

confidence: 99%

See 1 more Smart Citation

Biological drug therapy for ocular angiogenesis: Anti‐VEGF agents and novel strategies based on nanotechnology

Formica

Alfonso

Palma

2021

Pharmacology Res & Perspec

View full text Add to dashboard Cite

show abstract

“…Nevertheless, previous work conducted in our group has indicated that the surface availability of maleimide groups might actually be lower than expected [ 45 ], probably due to the miscibility of PEG and PLGA [ 49 , 50 ] that leads to the solubilization of the maleimide groups in the polymer matrix of the NPs and thus their inaccessibility for reaction with thiolyated cRGD. Cytotoxicity of PLGA-based NPs, incubated with HUVECs and other cell types, was reported by us and other groups to be negligible [ 51 , 52 , 53 , 54 ], and the coupling of cRGD to the surface of PLGA NPs is not expected to cause cytotoxicity as discussed by Graf et al [ 23 ].…”

Section: Discussionmentioning

confidence: 93%

Endothelial Cell Targeting by cRGD-Functionalized Polymeric Nanoparticles under Static and Flow Conditions

et al. 2020

View full text Add to dashboard Cite

Since αvβ3 integrin is a key component of angiogenesis in health and disease, Arg-Gly-Asp (RGD) peptide-functionalized nanocarriers have been investigated as vehicles for targeted delivery of drugs to the αvβ3 integrin-overexpressing neovasculature of tumors. In this work, PEGylated nanoparticles (NPs) based on poly(lactic-co-glycolic acid) (PLGA) functionalized with cyclic-RGD (cRGD), were evaluated as nanocarriers for the targeting of angiogenic endothelium. For this purpose, NPs (~300 nm) functionalized with cRGD with different surface densities were prepared by maleimide-thiol chemistry and their interactions with human umbilical vein endothelial cells (HUVECs) were evaluated under different conditions using flow cytometry and microscopy. The cell association of cRGD-NPs under static conditions was time-, concentration- and cRGD density-dependent. The interactions between HUVECs and cRGD-NPs dispersed in cell culture medium under flow conditions were also time- and cRGD density-dependent. When washed red blood cells (RBCs) were added to the medium, a 3 to 8-fold increase in NPs association to HUVECs was observed. Moreover, experiments conducted under flow in the presence of RBC at physiologic hematocrit and shear rate, are a step forward in the prediction of in vivo cell–particle association. This approach has the potential to assist development and high-throughput screening of new endothelium-targeted nanocarriers.

show abstract

“…PLGA NPs were developed for the delivery of fluoromethalone [92] and aceclofenac [93]. No significant cytotoxicity of PLGA NPs were found in vitro and in vivo [128]. Compared to a standard drug formulation, PLGA NPs increased drug bioavailability, providing better drug efficacy.…”

Section: Synthetic Derived Polymer-based Nanoparticlesmentioning

confidence: 99%

Advances and limitations of drug delivery systems formulated as eye drops

Jumelle

Gholizadeh

Annabi

et al. 2020

Journal of Controlled Release

218

125

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Effect of nanoencapsulation using poly (lactide-co-glycolide) (PLGA) on anti-angiogenic activity of bevacizumab for ocular angiogenesis therapy

Cited by 57 publications

References 33 publications

Biological drug therapy for ocular angiogenesis: Anti‐VEGF agents and novel strategies based on nanotechnology

Biological drug therapy for ocular angiogenesis: Anti‐VEGF agents and novel strategies based on nanotechnology

Endothelial Cell Targeting by cRGD-Functionalized Polymeric Nanoparticles under Static and Flow Conditions

Advances and limitations of drug delivery systems formulated as eye drops

Contact Info

Product

Resources

About